EGFR and non-small cell lung carcinoma: The latter is currently often limited to screening for exon 19 deletions and L858R substitution in EGFR-mutated patients undergoing surgery due to proof of eligibility for adjuvant osimertinib therapy in completely resected early-stage NSCLC patients [34].